Metavia, Dong-A ST Affiliate, Expands Global Patents for MASH Treatment Compound

"48 Global Patents Registered and Filed"

Metavia, an affiliate of Dong-A ST, announced on March 13 that it has expanded the global patent portfolio for 'Vanoglifel (DA-1241)', a treatment currently under development for metabolic dysfunction-associated steatohepatitis (MASH).

Metavia stated, “A total of 48 patents have been registered and filed in countries including the United States, Europe, Japan, and China. Through this, Vanoglifel is expected to be protected by patents at least until 2035, and there is also the possibility that the patent period may be further extended in the future.”

Vanoglifel is a first-in-class oral synthetic drug based on the GPR119 mechanism of action, currently being developed for indications including MASH and type 2 diabetes.

Meanwhile, Metavia is also expanding the patent portfolio for DA-1726, which is under development as an obesity treatment. A total of 39 patents have been registered or filed for DA-1726 in the United States and other major countries worldwide. The company plans to establish a global intellectual property foundation for DA-1726 through 2041.

This content was produced with the assistance of AI translation services.